GlassScriptPhysician profile
Erjola Balliu
NPI 1194967851
$2,382.35
in general payments reported to CMS, 2019-2025
26 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.58 · 2020: $195 · 2021: $519 · 2022: $376 · 2023: $287 · 2024: $304 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793 · Travel and Lodging: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.64 |
| Travel and Lodging | $475.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $699.45 | 2024-2025 | Minimed 780g |
| Lilly USA, LLC | $359.17 | 2020-2023 | Jardiance |
| Nevro Corp. | $185.07 | 2022-2024 | Senza |
| Tandem Diabetes Care, INC. | $183.70 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $172.18 | 2021-2023 | Ozempic |
| Sanofi-Aventis U.S. LLC | $169.67 | 2020-2023 | |
| Abbott Laboratories | $119.76 | 2021-2024 | Freestyle Libre 3 |
| Beta Bionics, INC. | $55.77 | 2024 | Ilet Bionic Pancreas |
| Pfizer INC. | $55.00 | 2022 | |
| Antares Pharma, INC. | $48.48 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $42.00 | 2022 | |
| Amneal Pharmaceuticals LLC | $32.12 | 2021-2023 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $26.98 | 2023 | |
| Dexcom, INC. | $25.84 | 2019-2020 | |
| Insulet Corporation | $23.91 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $22.41 | 2021 | |
| Sequel Med Tech, LLC | $21.58 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $21.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.88 | 2023 | |
| Endo Pharmaceuticals INC. | $16.26 | 2023 | Supprelin |
| Ascensia Diabetes Care US INC. | $15.81 | 2022 | |
| Mannkind Corporation | $14.47 | 2021 | |
| Amgen INC. | $13.89 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.73 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.66 | 2020 | |
| Medtronic Minimed, INC. | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erjola Balliu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.